CFSAN Constituent Update
January 16, 2014
FDA has decided to reopen, for 60 days, the comment period for specific portions of its final guidance for clinical investigators, sponsors, and institutional review boards (IRBs), entitled “Investigational New Drug Applications (INDs) -- Determining Whether Human Research Studies Can Be Conducted Without an IND,” which was announced in the September 10, 2013 Federal Register. FDA will reopen the comment period only for subsections of the final guidance that address the applicability of the IND regulations to clinical research studies involving cosmetics and foods (including dietary supplements). The Agency is taking this action in response to requests that it provide an additional opportunity to submit comments on these portions of the guidance.
FDA will publish a notice in the Federal Register to announce the reopening of the comment period and will issue a Constituent Update when the exact date of the reopening of the comment period is known.
- Investigational New Drug Applications (INDs) —Determining Whether Human Research Studies Can Be Conducted Without an IND